Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan V Boddy

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|September 28, 2018
A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation StudyJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Expert Opinion on Drug Metabolism & Toxicology|August 5, 2017
Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsJeffry Adiwidjaja, Andrew J McLachlan, Alan V Boddy
Frontiers in Pharmacology|February 22, 2020
Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in PaediatricsJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Clinical Pharmacokinetics|January 25, 2019
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's WortJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Investigational New Drugs|August 2, 2003
Chemotherapy individualizationGareth J Veal, Sally A Coulthard, Alan V Boddy
Journal of Immunological Methods|April 21, 2009
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasmaDavid Jamieson, Nicola Cresti, Mark W Verrill, et al.
Pharmacogenomics|October 30, 2016
The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancerXiaoman Liu, Jane Beith, Siew-Kee Low, et al.
British Journal of Clinical Pharmacology|September 18, 2021
Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimensJeffry Adiwidjaja, Annette S Gross, Alan V Boddy, et al.
Journal of Clinical Pharmacology|April 23, 2022
Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With ImatinibJeffry Adiwidjaja, Josephine A Adattini, Alan V Boddy, et al.
European Journal of Clinical Pharmacology|September 1, 2018
The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patientsHannah Yejin Kim, Gareth J Veal, Fanfan Zhou, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
CPT: Pharmacometrics & Systems Pharmacology|September 28, 2018
A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation StudyJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Expert Opinion on Drug Metabolism & Toxicology|August 5, 2017
Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsJeffry Adiwidjaja, Andrew J McLachlan, Alan V Boddy
Frontiers in Pharmacology|February 22, 2020
Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in PaediatricsJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Clinical Pharmacokinetics|January 25, 2019
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's WortJeffry Adiwidjaja, Alan V Boddy, Andrew J McLachlan
Investigational New Drugs|August 2, 2003
Chemotherapy individualizationGareth J Veal, Sally A Coulthard, Alan V Boddy
Journal of Immunological Methods|April 21, 2009
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasmaDavid Jamieson, Nicola Cresti, Mark W Verrill, et al.
Pharmacogenomics|October 30, 2016
The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancerXiaoman Liu, Jane Beith, Siew-Kee Low, et al.
British Journal of Clinical Pharmacology|September 18, 2021
Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimensJeffry Adiwidjaja, Annette S Gross, Alan V Boddy, et al.
Journal of Clinical Pharmacology|April 23, 2022
Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARS-CoV-2 Infection: A Case Study With ImatinibJeffry Adiwidjaja, Josephine A Adattini, Alan V Boddy, et al.
European Journal of Clinical Pharmacology|September 1, 2018
The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patientsHannah Yejin Kim, Gareth J Veal, Fanfan Zhou, et al.
Pageof 9